STUDY OBJECTIVES: Sleep problems are frequently associated with childhood ADHD, as indicated by numerous polysomnographic investigations showing increased nocturnal movements, reduced sleep efficiency, and decreased percentage of REM sleep (although findings are not consistent over all studies). Data on objective and subjective sleep parameters in adults with ADHD are sparse, and to date the impact of stimulants, the most widely used pharmacological treatment for ADHD, on sleep in adults with ADHD has not been examined. Thus the objectives of our study were to assess objective and subjective sleep parameters in adults with ADHD and the impact of stimulant medication on sleep. DESIGN: Two-group comparison and open-label therapy study. PARTICIPANTS: We enrolled 34 nonmedicated patients with ADHD, of whom 24 were without current comorbid psychiatric disorders, and 34 sex- and gender-matched control subjects without current psychiatric disorders or psychotropic medication. INTERVENTIONS: Ten patients were treated with methylphenidate over > or =26 days with a mean daily dose of 36.7 +/- 11.2 mg. MEASUREMENTS: Polysomnographic recording over 2 consecutive nights as well as assessments of subjective sleep parameters were performed in all patients and controls before treatment and reassessed in those patients receiving methylphenidate. RESULTS: Compared to controls untreated patients showed increased nocturnal activity, reduced sleep efficiency, more nocturnal awakenings and reduced percentage of REM sleep. Treatment with methylphenidate resulted in increased sleep efficiency as well as a subjective feeling of improved restorative value of sleep. CONCLUSIONS: Sleep problems in patients with ADHD continue from childhood to adulthood, with similar objective sleep characteristics in adults and children with ADHD. Medication with methylphenidate appears to have beneficial effects on sleep parameters in adults with ADHD.
STUDY OBJECTIVES: Sleep problems are frequently associated with childhood ADHD, as indicated by numerous polysomnographic investigations showing increased nocturnal movements, reduced sleep efficiency, and decreased percentage of REM sleep (although findings are not consistent over all studies). Data on objective and subjective sleep parameters in adults with ADHD are sparse, and to date the impact of stimulants, the most widely used pharmacological treatment for ADHD, on sleep in adults with ADHD has not been examined. Thus the objectives of our study were to assess objective and subjective sleep parameters in adults with ADHD and the impact of stimulant medication on sleep. DESIGN: Two-group comparison and open-label therapy study. PARTICIPANTS: We enrolled 34 nonmedicated patients with ADHD, of whom 24 were without current comorbid psychiatric disorders, and 34 sex- and gender-matched control subjects without current psychiatric disorders or psychotropic medication. INTERVENTIONS: Ten patients were treated with methylphenidate over > or =26 days with a mean daily dose of 36.7 +/- 11.2 mg. MEASUREMENTS: Polysomnographic recording over 2 consecutive nights as well as assessments of subjective sleep parameters were performed in all patients and controls before treatment and reassessed in those patients receiving methylphenidate. RESULTS: Compared to controls untreated patients showed increased nocturnal activity, reduced sleep efficiency, more nocturnal awakenings and reduced percentage of REM sleep. Treatment with methylphenidate resulted in increased sleep efficiency as well as a subjective feeling of improved restorative value of sleep. CONCLUSIONS: Sleep problems in patients with ADHD continue from childhood to adulthood, with similar objective sleep characteristics in adults and children with ADHD. Medication with methylphenidate appears to have beneficial effects on sleep parameters in adults with ADHD.
Authors: Louise M O'Brien; Cheryl R Holbrook; Carolyn B Mervis; Carrie J Klaus; Jennifer L Bruner; Troy J Raffield; Jennifer Rutherford; Rochelle C Mehl; Mei Wang; Andrew Tuell; Brittany C Hume; David Gozal Journal: Pediatrics Date: 2003-03 Impact factor: 7.124
Authors: Louise M O'Brien; Anna Ivanenko; Valerie McLaughlin Crabtree; Cheryl R Holbrook; Jennifer L Bruner; Carrie J Klaus; David Gozal Journal: Sleep Med Date: 2003-07 Impact factor: 3.492
Authors: P Retz-Junginger; W Retz; D Blocher; R-D Stieglitz; T Georg; T Supprian; P H Wender; M Rösler Journal: Nervenarzt Date: 2003-11 Impact factor: 1.214
Authors: Louise Margaret O'Brien; Anna Ivanenko; Valerie McLaughlin Crabtree; Cheryl Robin Holbrook; Jennifer Leigh Bruner; Carrie Joann Klaus; David Gozal Journal: Pediatr Res Date: 2003-05-07 Impact factor: 3.756
Authors: Alice M Gregory; Jessica C Agnew-Blais; Timothy Matthews; Terrie E Moffitt; Louise Arseneault Journal: J Clin Child Adolesc Psychol Date: 2016-08-02
Authors: Sara S Frye; Julio Fernandez-Mendoza; Susan L Calhoun; Alexandros N Vgontzas; Duanping Liao; Edward O Bixler Journal: Sleep Date: 2018-10-01 Impact factor: 5.849